Neuland Laboratories Limited (NSE:NEULANDLAB)

Market Cap	284.74B +73.4%
Revenue (ttm)	23.72B +78.3%
Net Income	4.98B +182.6%
EPS	388.01 +182.7%
Shares Out	n/a
PE Ratio	57.20
Forward PE	55.34
Dividend	34.00 (0.18%)
Ex-Dividend Date	Jul 24, 2026

Volume	88,421
Open	22,915
Previous Close	22,855
Day's Range	22,123 - 23,054
52-Week Range	11,500 - 23,500
Beta	-0.32
Analysts	Strong Buy
Price Target	24,334.75 (+9.54%)
Earnings Date	Aug 5, 2026

About Neuland Laboratories

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 2,183
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NEULANDLAB

Financial Performance

In fiscal year 2026, Neuland Laboratories's revenue was 20.23 billion, an increase of 36.98% compared to the previous year's 14.77 billion. Earnings were 3.64 billion, an increase of 39.94%.

Analyst Summary

According to 4 analysts, the average rating for NEULANDLAB stock is "Strong Buy." The 12-month stock price target is ₹24,335, which is an increase of 9.54% from the latest price.

Price Target

₹24,335

(9.54% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 10, 2026

Data Sources Report a data error